Sight Sciences, Inc.

Sight Sciences, Inc. (NASDAQ: SGHT) is a medical device company focused on developing transformative interventional technologies for the treatment of glaucoma and dry eye disease. The company operates through two primary business segments: Interventional Glaucoma and Interventional Dry Eye.

In the Interventional Glaucoma segment, Sight Sciences markets the OMNI Surgical System and SION Surgical Instrument, both designed to enable minimally invasive glaucoma surgery (MIGS) procedures. OMNI is a handheld, single-use device that enables comprehensive procedures to reduce intraocular pressure in patients with primary open-angle glaucoma by addressing all three known areas of resistance in the eye's conventional outflow pathway. SION is a bladeless, manually operated instrument used to excise trabecular meshwork tissue. The company estimates the annual addressable U.S. market opportunity for interventional glaucoma products at approximately six billion dollars, comprising one billion in combination cataract procedures and five billion in standalone procedures.

The Interventional Dry Eye segment centers on the TearCare System, a proprietary device designed to treat meibomian gland disease through localized heat therapy and mechanical expression of gland obstructions. The TearCare system consists of a reusable SmartHub controller and disposable SmartLids therapeutic eyelid devices. The U.S. market for dry eye treatments was valued at 2.4 billion dollars in 2025.

Sight Sciences maintains a direct sales organization in the United States, United Kingdom, and Germany, with over 100 commercial professionals dedicated to sales, marketing, training, and professional relations as of December 31, 2025. The company sells OMNI and SION primarily to ambulatory surgery centers and hospital outpatient departments, while TearCare is sold to both optometry and ophthalmology practices. The company has established robust clinical trial programs supporting its products, including completed randomized controlled trials and real-world evidence studies published in peer-reviewed journals. Medicare coverage exists for combination cataract procedures in five of seven MAC jurisdictions, with ongoing efforts to expand reimbursement coverage across additional payors and indications. The company's website is www.sightsciences.com.